The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its mid-December bear gap, after which it hit a Jan. 17, 52-week low of $78.17 amid ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

Medicinalselskabet Novo Nordisk overgik markedets forventninger med et overskud på 101 milliarder sidste år. Og analytikere peger på, at selskabet fortsat vil vokse massivt de næste år.

Eli Lilly er danske Novo Nordisks største konkurrent på medicinalmarkedet inden for diabetes og overvægt. Novo offentliggjorde sit årsregnskab onsdag morgen. Det viste et overskud på 101 milliard ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. While popular drugs like Ozempic and Wegovy are ...